The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Gamma-Dynacare Medical Laboratories is a Canadian medical laboratory services company based in Brampton, Ontario, Canada. Dynacare operates laboratories in Brampton, Bowmanville, London, Ottawa, Thunder Bay, Pointe-Claire, Laval, and Winnipeg. In addition to the main laboratories Dynacare operates patient services centers throughout Ontario, Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Dynacare is an operational partnership founded in 1997 as Gamma-Dynacare between: Dynacare Laboratories; Gamma North Peel Partnership Inc.; and Bio-Science Laboratory (Ontario) Limited. In 2002 Dynacare Laboratories (one of the Dynacare partners) was acquired by LabCorp for $480-million (U.S.) while also assuming Dynacare debt worth $205-million. In 2015, it rebranded itself back to Dynacare. In 2011 Dynacare acquired the medical laboratory division of Warnex Inc. (TSX:WNX) for $7.5 Million. In 2023 Dynacare acquired the medical laboratories in British Columbia known as Valley Medical Laboratories. This increased the Dynacare presence in British Columbia by adding about 12 locations in Kelowna and throughout the Okanagan Valley.
Prof. Rode's second main field of research lies in the area of bioinorganic chemistry, in particular abiogenesis. At the end of the 1980s Prof. Rode and his coworkers discovered the salt induced peptide formation reaction as a simple route to synthesis peptides from amino acid monomers under prebiotic conditions. Instead of enzymes transition metals act as catalyst to induce peptide formation in highly concentrated aqueous NaCl solution, with copper (II) showing the highest catalytic activity. Typically, evaporation cycle experiments have been carried out to mimic day/night cycles on shore and in lagoons, thereby generating supersaturated solutions. Since such solutions have a tendency to dilute themselves, the thermodynamic and kinetic unfavourable peptide formation reaction is promoted. The research conducted by Prof. Rode investigates the properties of the salt induced peptide formation reaction under various conditions, highlighting also its possible connection to biohomochirality. Furthermore, Prof. Rode also carried out Miller–Urey experiments, taking new insights of the composition of the primordial atmosphere into account. It was shown that peptides may also form in a neutral atmosphere (CO2/N2/H2O) subject to electric discharges.
=== Common usage === "Nanoscale" is usually understood to be the range from 1 to 100 nm because the novel properties that differentiate particles from the bulk material typically develop at that range of sizes. For some properties, like transparency or turbidity, ultrafiltration, stable dispersion, etc., substantial changes characteristic of nanoparticles are observed for particles as large as 500 nm. Therefore, the term is sometimes extended to that size range.
Sources: en.wikipedia.org
18 September – A study published in Nature Neuroscience, using mouse embryos and human pluripotent stem cells, finds that the forebrain and midbrain develop from a different progenitor cell lineage from the hindbrain, challenging the long-standing model of a single progenitor population for the entire brain. The authors propose that the brain is a composite organ arising from two developmentally distinct systems that may have been evolutionarily conserved for more than 550 million years.
As Canadian pathology society did not have a registry, interested Canadian medical technologists sat for the Amereican ASCP MT certification instead. In 1939, the BOR publishes the first book outlining the educational curriculum for medical technologists entitled Curriculum for Schools of Medical Technology. In 1940, as other organizations began using the same designations, the initials MT(ASCP) were used. In 1944, due to travel wartime restrictions from World War II, the practical component of the certification was discontinued. In 1948, the written essay portion of the certification was deemed too cumbersome to assess, and the certification was switched to a multiple choice and true-false assessment that could be graded on a machine and provide exam statistics. In 1949, the BOR changed the exam format to a 200 multiple choice question exam as the multiple choice questions were found to be a more reliable indicator than true-false questions. In 1949, the BOR also created the Board of Schools (BOS) for registering schools. In 1958, BoR and ASMT assisted with the reclassification of medical technologists, putting them at the professional level in the Civil Service and allowing medical technologists to gain commission status in the US military. In 1962, the BoR began requiring 3 years of college for the MT certification. In 1972, the BoR began requiring a Bachelor's degree for the MT certification. There were 100,000 certificates issued by 1975, 200,000 by 1980, 300,000 by 1991, 400,000 by 2005, and 500,000 by 2014.
=== Bacteria === Some bacteria have been shown to be able to turn morphine into closely related drugs, including hydromorphone and dihydromorphine among others. The bacterium Pseudomonas putida serotype M10 produces a naturally occurring NADH-dependent morphinone reductase that can work on unsaturated 7,8 bonds, with result that, when these bacteria are living in an aqueous solution containing morphine, significant amounts of hydromorphone form, as it is an intermediary metabolite in this process; the same goes for codeine being turned into hydrocodone.
Sources: en.wikipedia.org
The Perceived Stress Scale was developed to measure the degree to which situations in one’s life are appraised as stressful. Psychological stress has been defined as the extent to which persons perceive (appraise) that their demands exceed their ability to cope. The PSS was published in 1983, and has become one of the most widely used psychological instruments for measuring nonspecific perceived stress. It has been used in studies assessing the stressfulness of situations, the effectiveness of stress-reducing interventions, and the extent to which there are associations between psychological stress and psychiatric and physical disorders. The PSS predicts both objective biological markers of stress and increased risk for disease among persons with higher perceived stress levels. For example, those with higher scores (suggestive of chronic stress) on the PSS fend worse on biological markers of aging, cortisol levels, immune markers, depression, infectious disease, wound healing, and prostate-specific antigen levels in men. The Perceived Stress scale was developed by Sheldon Cohen and his colleagues.
== Structure == In humans, the gene for StAR is located on chromosome 8p11.23 and the protein has 285 amino acids. The signal sequence of StAR that targets it to the mitochondria is clipped off in two steps with import into the mitochondria. Phosphorylation at the serine at position 195 increases its activity. The domain of StAR important for promoting cholesterol transfer is the StAR-related transfer domain (START domain). StAR is the prototypic member of the START domain family of proteins and is thus also known as STARD1 for "START domain-containing protein 1". It is hypothesized that the START domain forms a pocket in StAR that binds single cholesterol molecules for delivery to P450scc. The closest homolog to StAR is MLN64 (STARD3). Together they comprise the StarD1/D3 subfamily of START domain-containing proteins.
Eosin is the name of several fluorescent acidic compounds which bind to and form salts with basic, or eosinophilic, compounds like proteins containing basic amino acid residues such as histidine, arginine and lysine, and stains them dark red or pink as a result of the actions of bromine on eosin. In addition to staining proteins in the cytoplasm, it can be used to stain collagen and muscle fibers for examination under the microscope. Structures that stain readily with eosin are termed eosinophilic. In the field of histology, Eosin Y is the form of eosin used most often as a histologic stain.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.